Exagen Inc

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exagen Inc reports robust Q1 revenue growth and strategic expansion

Exagen Inc's Q1 performance reflects strong revenue growth and improved financial outlook, driven by enhanced ASP and strategic initiatives.
Despite challenges in initial demand impact and regulatory monitoring, the company remains optimistic about future growth prospects and market positioning.
With a focus on innovation, market expansion, and operational efficiency, Exagen Inc aims to capitalize on opportunities for sustained growth and competitive advantage.

Exagen Inc reports strong Q2 performance, eyes growth through innovation

Exagen Inc's Q2 performance reflects significant improvement in financial metrics, revenue growth, and progress towards profitability, driven by increased clinical adoption and strategic initiatives.
The company's focus on innovation, market expansion, and customer engagement through new markers, biopharma contracts, and educational campaigns positions them for sustained growth and competitive advantage.
While challenges persist in achieving profitability and market acceptance, Exagen's proactive approach to addressing these hurdles and leveraging opportunities bodes well for their future success and market leadership.

Exagen Inc reports progress in revenue growth and innovation initiatives

Exagen Inc's Q3 2024 earnings call highlighted both achievements and challenges, with a focus on revenue growth, innovation, and operational improvements. The company is poised for growth with upcoming product launches and a strategic approach to enhancing the clinician experience. Challenges remain in achieving profitability and managing capacity expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022. John Aballi, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).

Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.  Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm.

Exagen Announces Appointment of John Aballi as CEO

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In this role, Dr. Concoff will lead the company's rheumatoid arthritis medical initiatives, including the AVISE® RADR platform (Rheumatoid Arthritis Drug Response). Dr. Concoff will be a key principal in strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures, as well as the advancement of innovative access partnerships with payors and governments globally.

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2022, being held November 10-14, 2022, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory University has led to a publication in Nature, found here. Exagen's clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection.

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Exagen Inc. (NASDAQ:XGN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Griffin Soriano - William Blair Ross Osborn - Cantor Fitzgerald Ryan Douglas Good afternoon, and thank you for joining us today. Earlier today, Exagen Inc. released financial results for the quarter ended June 30th, 2022.

Exagen Inc. (XGN) CEO Ron Rocca on Q2 2022 Results - Earnings Call Transcript

Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic diagnostic test for rheumatoid arthritis using the AVISE® RADR platform. The goal of the Treatment stratIfication using Gene Expression profiling in Rheumatoid arthritis (TiGER) study is to assess whether certain biomarkers from synovial biopsies of inflamed joint tissue accurately predict response to antirheumatic medications. The TiGER study is the next step in Exagen's process of bringing AVISE® RADR to market.

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual Growth Conference, which takes place August 8-11, 2022, in Boston at the InterContinental Boston Hotel. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will present on Thursday, August 11th, at 12:00 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.

Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing enables decisive clinical action in the differential diagnosis for lupus. The Complement Activation Products vs. Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus (CAPSTONE) study is the largest comparative utility study in lupus diagnosis and was published in the Journal of Managed Care & Specialty Pharmacy. The study leveraged multiple external databases encompassing electronic health records and linked insurance claims data on nearly 50,000 patient tests with AVISE or standard of care labs from hundreds of rheumatologists across the U.S., comparing diagnosis, treatment, and cost of care outcomes for new patients tested with AVISE Lupus and those tested with a traditional ANA (tANA) approach, including specific autoantibodies. The findings revealed that the AVISE Lupus test is more clinically effective, both for patients who test positive and those who test negative, as compared to the current standard of care.

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC's national provider network, providing enhanced care to their approximately 7.5 million commercial lives. The agreement, effective July 1, 2022, with MediNcrease will make AVISE® tests, including AVISE® Lupus and AVISE® CTD accessible through MediNcrease's client base of regional and national health plans, insurance companies, employers, municipalities, third-party administrators, unions, and other companies involved in the management of medical claims.

Exagen Inc. Expands Coverage with MediNcrease

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth Stock Conference, which takes place June 6-9, 2022, in Chicago at the Loews Chicago Hotel. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will present on Thursday, June 9th, at 12:40 PM CT. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.

Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered service with Alivio Health, providing enhanced care to their 150,000 members. The agreement also makes AVISE® diagnostic testing available as an in-network benefit.

Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus

Exagen Inc. (NASDAQ:XGN ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Chief Operating Officer Conference Call Participants Brian Weinstein - William Blair Kyle Mikson - Canaccord Operator Greetings, ladies and gentlemen, and welcome to the Exagen, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this conference is being recorded.

Exagen Inc. (XGN) CEO Ron Rocca on Q1 2022 Results - Earnings Call Transcript

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has provided pricing for AVISE® Lupus. Noridian's decision to price AVISE Lupus follows the approval by the American Medical Association (AMA) CPT® Editorial Panel of Proprietary Laboratory Code (PLA) code 0312U for AVISE Lupus. The PLA code has an effective date of April 1, 2022.

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March

Exagen Inc. Reports First Quarter 2022 Results

SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE).

Exagen Announces Five-Week Campaign for Lupus Awareness Month

SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).

Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group's Q2 Conference, which takes place May 3rd - 4th, 2022, in New York City at the Westin New York Grand Central Hotel. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will present on Wednesday, May 4th, at 2:00 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.

Exagen Inc. to Participate in Investor Summit Group's Q2 Conference

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members. The agreement includes Exagen's AVISE® Lupus and AVISE® CTD tests making AVISE diagnostic testing available as an in-network benefit.

Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as an in-network benefit for patients. Effective June 1, 2022, AVISE test offerings become an in-network, covered benefit with Centene Corporation, including its subsidiary WellCare Health Plans, providing enhanced care to over 22.7 million members.

Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives

Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin Percent, Adopters, and Ordering Healthcare Providers Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin Percent, Adopters, and Ordering Healthcare Providers

Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results

SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB) with appointment of seven doctors and rheumatology experts. The SAB includes Stanley Cohen, MD; Andrew Concoff, MD, FACR, CAQSM; Kevin Deane, MD, PhD; Paul J. DeMarco, MD; Harris Perlman, PhD; Eric Ruderman, MD; and Marina Sirota, PhD.

News for Exagen Inc Stock (XGN)